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Abstract: BACKGROUND: This study sought to determine whether the 1-year differences in major
adverse cardiac event between a stent eluting biolimus from a biodegradable polymer and bare-metal
stents (BMSs) in the COMFORTABLE trial (Comparison of Biolimus Eluted From an Erodible Stent
Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) were sustained during
long-term follow-up. METHODS AND RESULTS: A total of 1161 patients were randomly assigned
to biolimus-eluting stent (BES) and BMS at 11 centers, and follow-up rates at 2 years were 96.3%. A
subgroup of 103 patients underwent angiography at 13 months. At 2 years, differences in the primary end
point of cardiac death, target-vessel myocardial infarction, and target lesion revascularization continued
to diverge in favor of BES-treated patients (5.8%) compared with BMS-treated patients (11.9%; hazard
ratio = 0.48; 95% confidence interval, 0.31-0.72; P < 0.001) with a significant risk reduction during
the second year of follow-up (hazard ratio 1-2 years = 0.45; 95% confidence interval, 0.20-1.00; P =
0.049). Differences in the primary end point were driven by a reduction in target lesion revascularization
(3.1% versus 8.2%; P < 0.001) and target-vessel reinfarction (1.3% versus 3.4%; P = 0.023). The
composite of death, any reinfarction and revascularization (14.5% versus 19.3%; P = 0.03), and cardiac
death or target-vessel myocardial infarction (4.2% versus 7.2%; P = 0.036) were less frequent among
BES-treated patients compared with BMS-treated patients. The 13-month angiographic in-stent percent
diameter stenosis amounted to 12.0 ± 7.2 in BES- and 39.6 ± 25.2 in BMS-treated lesions (P < 0.001).
CONCLUSIONS: Among patients with ST-segment-elevation myocardial infarction undergoing primary
percutaneous coronary intervention, BES continued to improve cardiovascular events compared with
BMS beyond 1 year. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique
identifier: NTC00962416.
DOI: 10.1161/CIRCINTERVENTIONS.113.001440
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Primary percutaneous coronary intervention (PCI) is the reperfusion therapy of choice for patients with acute 
ST-segment–elevation myocardial infarction (STEMI).1,2 
Early-generation drug-eluting stents (DES) have been shown 
more effective than bare-metal stents (BMS), but they were 
associated with an increased risk of very late stent thrombo-
sis (ST).3 Polymers components applied to the stent surface 
to enable delayed drug release have been implicated in the 
pathogenesis of delayed arterial healing and vessel remodeling 
owing to chronic inflammation. More recently, new-genera-
tion DESs with more biocompatible durable and biodegrad-
able polymers have largely overcome this limitation, although 
the long-term safety profile of these devices particularly 
among patients with STEMI has not been established to date.
Biolimus-eluting stents (BES) are new-generation DES with 
biodegradable polymer for drug release, which is resorbed 
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Methods and Results—A total of 1161 patients were randomly assigned to biolimus-eluting stent (BES) and BMS at 11 
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intervention, BES continued to improve cardiovascular events compared with BMS beyond 1 year.
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during a period of 6 to 9 months. In an all comers trial,4 a sig-
nificant reduction of very late ST vis-à-vis a durable polymer–
based early-generation sirolimus-eluting stent was observed 
during long-term follow-up. A dedicated randomized trial in 
patients with STEMI comparing BES with BMS of otherwise 
identical design showed a reduction in major adverse cardiac 
events (MACEs) at 1 year owing to a lower risk of target-
lesion revascularization and target-vessel myocardial infarc-
tion.5 Whether the clinical benefits of BES over BMS remain 
sustained during long-term follow-up is unknown. The pur-
pose of this study is to report the long-term clinical outcome 
of patients included in Comparison of Biolimus Eluted from 
an Erodible Stent Coating with Bare-Metal Stents in Acute 
ST-Elevation Myocardial Infarction (COMFORTABLE AMI) 
trial throughout 2 years and the results of the angiographic 
substudy performed 13 months after stent implantation (see 
the Data Supplement for a list of investigators).
Methods
Study Design
The study design of COMFORTABLE AMI trial has been reported 
elsewhere.5,6 Briefly, this is a multicenter, randomized, assessor-blind, 
superiority trial in patients with STEMI undergoing primary PCI reg-
istered at ClinicalTrials.gov (NTC00962416). Consecutive patients 
≥18 years with acute ST-segment elevation of ≥1 mm in ≥2 contigu-
ous leads, true posterior myocardial infarction, or new left bundle 
branch block were eligible for randomization in the presence of ≥1 
culprit lesion within the infarct vessel. There was no limit about the 
number of treated lesions, vessels, or complexity. Exclusion crite-
ria were presence of mechanical complications of acute myocardial 
infarction, known allergy to any study medication, use of vitamin 
K-antagonists, planned surgery unless dual antiplatelet therapy could 
be maintained throughout the perisurgical period, history of bleeding 
diathesis or known coagulopathy, pregnancy, participation in another 
trial before reaching the primary end point, inability to provide in-
formed consent, and noncardiac comorbid conditions with life ex-
pectancy below 1 year. The study complied with the declaration of 
Helsinki and was approved by all institutional ethics committees. All 
patients provided written, informed consent.
Procedures
Randomization was performed via a Web-based system after diag-
nostic angiography. Patients were randomly assigned 1:1 to treatment 
with stents eluting biolimus from a biodegradable polylactic acid 
polymer (BioMatrix; Biosensors Europe SA, Morges, Switzerland) 
or BMSs of otherwise identical design (Gazelle; Biosensors Europe 
SA, Morges, Switzerland). Before stent implantation, thrombus aspira-
tion was recommended whenever aspiration was deemed technically 
feasible. Predilatation of the culprit lesion was left to the discretion 
of the operator. Complete revascularization of all lesions within the 
infarct vessel had to be performed with the randomly allocated study 
stent. Acetylsalicylic acid (≥250 mg) was given before the procedure. 
In centers where prasugrel was available, an initial dose of 60 mg (in-
cluding patients preloaded with clopidogrel) was given followed by a 
daily dose of 10 mg. If prasugrel was not available or contraindicated, 
clopidogrel was administered at a loading dose of 600 mg, followed by 
a dose of 75 mg twice daily for 7 days followed by a maintenance dose 
of 75 mg once daily. Dual antiplatelet therapy was prescribed for the 
duration of ≥1 year in all patients. During the procedure, unfraction-
ated heparin was given at a dose of at least 5000 international units or 
70 to 100 international units/kg or alternatively bivalirudin. The use of 
glycoprotein IIb/IIIa inhibitors was left to the discretion of the operator.
Data Management and Clinical End Points
Independent study monitors verified source data according to a pre-
specified monitoring plan.5 Data were stored in a central database 
(Cardiobase, Clinical Trials Unit and Department of Cardiology, 
Bern University Hospital, Switzerland and 2mT, Ulm, Germany). 
Follow-ups were scheduled at 30 days and 1 and 2 years, and patients 
were questioned about the occurrence of angina, any adverse events, 
recurrent hospitalizations, and cardiovascular medication intake. Any 
death, reinfarction, revascularization, ST, cerebrovascular accident, 
and bleeding event were independently adjudicated by a blinded 
clinical event committee. The prespecified primary end point was the 
device-oriented composite of cardiac death, target-vessel reinfarc-
tion, and ischemia-driven target-lesion revascularization within 12 
months. Detailed definitions of all primary and secondary end points 
were reported elsewhere.7
Angiographic Substudy
Five participating centers were selected as intracoronary imaging 
centers and recruited patients into the formal angiographic and intra-
coronary imaging substudy (Bern, Copenhagen, Geneva, Lugano, 
and Zurich). Patients enrolled in the COMFORTABLE AMI study 
were eligible for participating the angiographic substudy when the 
following criteria were fulfilled: age <90 years, hemodynamic stabil-
ity, preserved renal function (glomerular filtration rate >30 mL/min), 
thrombolysis in myocardial infarction flow ≥II of the infarct-related 
artery at the end of the intervention, coronary anatomy suitable for in-
tracoronary imaging, and agreement to undergo angiographic and intra-
coronary imaging follow-up at 13 months. All patients were scheduled 
for repeat angiography of the culprit lesion at 13 months after record-
ing of the primary clinical outcome. Coronary angiograms were re-
corded at baseline immediately after the procedure and at 13 months 
and were assessed at the core laboratory of Bern University Hospital. 
Patients received nitroglycerin before angiography, and measurements 
were performed on cineangiograms. The contrast-filled, untapered tip 
of the catheter was used for calibration. Quantitative measurements in-
cluded reference vessel diameter, minimal lumen diameter, and percent 
diameter stenosis. Digital angiograms were analyzed with the use of the 
software (QAngio XA Version 7.1; Medis, Leiden, The Netherlands). 
Quantitative coronary angiograms from patients returning for repeat an-
giography in the setting of ST were not included during the first 30 days.
WHAT IS KNOWN
•	Among patients with ST-elevation myocardial in-
farction undergoing primary percutaneous coronary 
intervention, biodegradable polymer biolimus-elut-
ing stents reduce major cardiovascular events com-
pared with bare-metal stents at 1 year.
•	The clinical effect of newer generation biodegrad-
able drug-eluting stent beyond 1 year after primary 
percutaneous coronary intervention is unknown.
WHAT THE STUDY ADDS
•	Biolimus-eluting stent is associated with a continued 
reduction of major cardiovascular events during the 
second year of follow-up.
•	Clinical differences were not only driven by a dif-
ference in efficacy but also by ischemic end points 
including cardiac death or target-vessel myocardial 
infarction.
•	Although 60% patients discontinued dual antiplate-
let therapy at 1 year, no difference in very late stent 
thrombosis was observed between biodegradable 
drug-eluting stent and bare-metal stents.
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Statistical Analysis
COMFORTABLE AMI trial was powered for superiority on the prima-
ry clinical end point at 1 year. All analyses were performed according 
to the intention-to-treat principle, with inclusion of all 1161 random-
ized patients in the analysis according to the originally allocated stent 
type. Medication intake at discharge and follow-up was reported as 
counts and percentages, and groups were compared using Fisher exact 
tests. Cox proportional hazards models were used to compare clinical 
outcomes between the allocated stents, with patients censored at the 
time of their last valid contact. Landmark Cox proportional hazards 
models were used to compare clinical outcomes between the allocated 
stents in different periods since PCI; the P value for the interaction 
compares the period before (eg, 30 days or 1 year) to the period after 
the landmark (eg, beyond 30 days or 1 year) using robust variance 
estimators. Analyses for MACE were repeated excluding the subgroup 
of patients enrolled in the COMFORTABLE Imaging substudy. All 
P values are 2-sided, and all analyses were performed with Stata 12.1. 
The sample size of the imaging subgroup was calculated to show supe-
riority of BES over BMS in terms of neointimal thickness as assessed 
by optical coherence tomography (not reported here).








Age, y 60.7±11.6 60.4±11.9
Male sex, n (%) 463 (80.5) 455 (78.2)
Body mass index, kg/m2 27.3±4.5 27.2±4.0
Cardiovascular risk factors
 Diabetes mellitus, n (%) 84 (14.6) 90 (15.5)
 Hypertension, n (%) 279 (48.5) 265 (45.5)
 Hyperlipidemia, n (%) 324 (56.6) 328 (56.7)
 Current smoker, n (%) 272 (47.9) 301 (52.3)
 Family history of CAD, n (%) 193 (34.3) 179 (31.3)
Clinical presentation
 Time from symptom onset to balloon inflation, min (IQR) 232 (164–380) 236 (163–400)
  0–6 h 421 (73.2) 421 (72.6)
  6–12 h 109 (19.0) 100 (17.2)
  12–24 h 45 (7.8) 59 (10.2)
 Time from hospital admission to balloon inflation, min (IQR) 44 (32–70) 44 (32–74)
 Killip class II, III, or IV, n/total n (%) 40 (7.0) 37 (6.4)
 Left ventricular ejection fraction, % 49±11 50±10
Lesion complexity
 Bifurcation lesion, n (%) 52 (9.0) 49 (8.4)
 Small vessel (reference vessel diameter ≤2.5 mm) 74 (12.9) 79 (13.7)
 Long lesion (lesion length ≥20 mm) 204 (35.7) 183 (31.7)
 SYNTAX MI score 15.1±8.2 14.8±8.1
 Lesions treated in infarct vessel, n 629 648
 Lesions treated per patient 1.1±0.3 1.1±0.4 0.61
 Baseline TIMI flow, n (%) 0.31
  0 or 1 437 (69.6) 423 (65.6)
  2 81 (12.9) 95 (14.7)
  3 110 (17.5) 127 (19.7)
 Primary PCI procedure
  No. of stents per lesion 1.32±0.61 1.26±0.60 0.16
  Stent length per lesion, mm 25.2±12.7 24.1±12.3 0.10
  Stent diameter per lesion, mm 3.2±0.4 3.2±1.1 0.42
  Direct stenting, n (%) 236 (37.6) 240 (37.3) 0.89
  Maximal balloon pressure, atm 15.2±3.5 15.1±3.4 0.50
  Thrombus aspiration, n (%) 350 (60.9) 374 (64.4) 0.22
 Final TIMI flow, n (%)
  0 or 1 3 (0.5) 3 (0.5) 0.70
  2 25 (4.0) 32 (5.0)
  3 601 (95.5) 611 (94.6)
CAD indicates coronary artery disease; IQR, interquartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention; and 
TIMI, thrombolysis in myocardial infarction.
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Results
A total of 1161 patients were randomly assigned to receive 
BES with biodegradable polymer (578 patients) or BMS 
(583 patients). Follow-up at 2 years was available in 96.7% 
of BES-treated patients and 95.9% of BMS-treated patients. 
Baseline clinical and procedural characteristics were well bal-
anced in both stent groups (Table 1). Compliance with recom-
mended durations of dual antiplatelet therapy is summarized 
in Table 2. Per protocol, dual antiplatelet therapy with either 
clopidogrel or prasugrel was recommended for ≥1 year. We 
observed no differences in dual antiplatelet therapy compli-
ance at any time point, and ≈18% of patients in both groups 
remained on thienopyridines throughout 2 years. No differ-
ences about the type of thienopyridine were noted between 
groups at any time point.
Clinical Outcomes During Long-Term Clinical 
Follow-Up
Long-term clinical outcomes are summarized in Table 3. At 
2 years, the primary end point of MACEs (cardiac death, 
target-vessel reinfarction, and ischemia-driven target-lesion 
revascularization) occurred in 5.8% of patients receiv-
ing BES and 11.9% of patients receiving BMS (hazard 
ratio [HR], 0.48; 95% confidence interval [CI], 0.31–0.72; 
P<0.001) (Figure 1A). Individual components of the pri-
mary end point showed significant differences in favor 
of BES for target-vessel reinfarction (1.3% versus 3.4%; 
HR, 0.37; 95% CI, 0.15–0.87; P=0.023) and ischemia-
driven target-lesion revascularization (3.1% versus 8.2%; 
HR, 0.36; 95% CI, 0.21–0.63; P<0.001) (Figure 1B–1D). 
The patient-oriented composite end point of all-cause death, 
any reinfarction, and any revascularization was observed in 
14.5% among BES-treated patients with STEMI and 19.3% of 
BMS-treated patients with STEMI (HR, 0.73; 95% CI, 0.55–
0.97; P=0.03). Cardiac death or target-vessel reinfarction was 
lower among patients receiving BES (4.2%) compared with 
patients receiving BMS (7.2%; HR, 0.58; 95% CI, 0.35–0.97; 
P=0.036) at 2 years. Rates of definite or definite and probable 
ST are shown in Figure 2 and were numerically but not statis-
tically lower with BES compared with BMS at 2 years.
Clinical Outcomes Beyond 1 Year of Follow-Up
Clinical outcomes between 1 and 2 years are summarized in 
Table 2 and Figure 3. The landmark analysis at 1 year shows 
that differences between stent types in terms of the primary 
end point MACE continued to favor patients treated with BES 
(1.7% versus 3.7%; HR, 0.45; 95% CI, 0.20–1.00; P=0.049) 
without evidence of interaction between the 2 time periods 
(Pinteraction=0.88). A sensitivity analysis excluding patients 
undergoing repeat angiography at 13 months showed a con-
sistent benefit of BES over BMS during the second year of 
follow-up (HR1-2 years, 0.45; 95% CI, 0.20–1.0; P=0.049). Dif-
ferences between stent types were not significant for cardiac 
death, target-vessel reinfarction, and ischemia-driven target-
lesion revascularization, although event rates were numeri-
cally lower for BES than BMS between 1 and 2 years. There 
were no differences in rates of very late definite (BES 0.6% 
versus BMS 0.4%; HR, 1.47; 95% CI, 0.25–8.83; P=0.67) 
and very late definite or probable ST (BES 0.8% versus BMS 
0.8%; HR, 0.98; 95% CI, 0.25–3.93; P=0.98).
Angiographic Results
A total of 103 patients were included into the angiographic sub-
study, and the results are shown in Table 4. Only few patients 
Table 2. Dual Antiplatelet Therapy Intake Throughout 2 Years
Biolimus-Eluting Stents (n=575) Bare-Metal Stents (n=582) P Value
At discharge, n (%) n=569 n=578
 Acetylsalicylic acid 568 (99.8%) 576 (99.7%) 1.00
 Clopidogrel 323 (56.8%) 327 (56.6%) 0.95
 Prasugrel 245 (43.1%) 248 (42.9%) 1.00
 Any dual antiplatelet therapy 567 (99.6%) 574 (99.3%) 0.69
At 30 d, n (%) n=560 n=570
 Acetylsalicylic acid 556 (99.3%) 565 (99.1%) 1.00
 Clopidogrel 323 (57.6%) 322 (56.5%) 0.72
 Prasugrel 240 (42.9%) 245 (43.0%) 1.00
 Any dual antiplatelet therapy 554 (98.9%) 559 (98.1%) 0.33
At 1 y, n (%) n=543 n=545
 Acetylsalicylic acid 530 (97.6%) 525 (96.3%) 0.29
 Clopidogrel 287 (52.9%) 266 (48.8%) 0.18
 Prasugrel 213 (39.2%) 223 (40.9%) 0.58
 Any dual antiplatelet therapy 490 (90.2%) 479 (87.9%) 0.24
At 2 y, n (%) n=530 n=525
 Acetylsalicylic acid 511 (96.4%) 498 (94.9%) 0.23
 Clopidogrel 71 (13.4%) 59 (11.2%) 0.30
 Prasugrel 29 (5.5%) 40 (7.6%) 0.17
 Any dual antiplatelet therapy 93 (17.5%) 93 (17.7%) 1.00
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of the angiographic cohort did not undergo protocol-mandated 
follow-up angiography at 13 months (13.2% for BES- and 
10% for BMS-treated patients). Reference vessel diameter 
and minimal lumen diameter were comparable in both groups 
after the procedure. At 13-month follow-up, percent diameter 
stenosis (in-stent, 12.02±7.23 versus 39.60±25.21; in-seg-
ment, 21.55±8.70 versus 41.29±24.10 mm) and in-segment 
(0.10±0.30 versus 0.71±0.75 mm; P<0.001) and in-stent late 
lumen loss (0.10±0.24 versus 0.97±0.75 mm, P<0.001) were 
lower in BES-treated lesion compared with BMS-treated 
lesions. As a result, there was a large difference in in-segment 
binary restenosis (0% versus 25.9%; P<0.001). The cumula-
tive distribution of % diameter stenosis stratified by stent type 
is shown in Figure 4.
Discussion
This study reports long-term clinical outcomes of new-gener-
ation DES with biodegradable polymer compared with BMS 
Table 3. Clinical Outcomes at 2 Years and Between 1 and 2 Years
Biolimus-Eluting Stents (n=575) Bare-Metal Stents (n=582) Hazard Ratio (95% CI) P Value
All events at 2 y
 Death 28 (4.9%) 32 (5.6%) 0.79 (0.53–1.46) 0.62
 Cardiac death 17 (3.0%) 25 (4.4%) 0.69 (0.37–1.27) 0.23
 Reinfarction 18 (3.3%) 28 (5.0%) 0.64 (0.35–1.16) 0.14
  Q-wave 6 (1.1%) 9 (1.6%) 0.67 (0.24–1.88) 0.45
  Non–Q-wave 12 (2.2%) 19 (3.4%) 0.63 (0.31–1.30) 0.21
 Target-vessel reinfarction 7 (1.3%) 19 (3.4%) 0.37 (0.15–0.87) 0.023
  Q-wave 4 (0.7%) 8 (1.4%) 0.50 (0.15–1.67) 0.26
  Non–Q-wave 3 (0.6%) 11 (2.0%) 0.27 (0.08–0.98) 0.046
 Cardiac death or target-vessel reinfarction 24 (4.2%) 41 (7.2%) 0.58 (0.35–0.97) 0.036
 Any TLR 19 (3.5%) 53 (9.5%) 0.35 (0.21–0.59) <0.001
 Ischemia-driven TLR 17 (3.1%) 46 (8.2%) 0.36 (0.21–0.63) <0.001
 Any TVR 26 (4.7%) 58 (10.4%) 0.44 (0.27–0.69) <0.001
 Ischemia-driven TVR 23 (4.2%) 51 (9.1%) 0.44 (0.27–0.72) 0.001
 Major adverse cardiac events* 33 (5.8%) 68 (11.9%) 0.48 (0.31–0.72) <0.001
 Death, any reinfarction, any revascularization 82 (14.5%) 110 (19.3%) 0.73 (0.55–0.97) 0.03
 Stroke 6 (1.6%) 4 (1.1%) 1.51 (0.54–4.25) 0.43
 Definite stent thrombosis 8 (1.4) 15 (2.6) 0.53 (0.23–1.26) 0.15
 Definite or probable stent thrombosis 18 (3.2%) 25 (4.4%) 0.72 (0.39–1.32) 0.29
All events between 1 and 2 y
 Death 10 (1.9%) 9 (1.7%) 1.11 (0.45–2.73) 0.82
 Cardiac death 1 (0.2%) 5 (0.9%) 0.20 (0.02–1.71) 0.14
 Reinfarction 7 (1.3%) 7 (1.4%) 0.99 (0.35–2.82) 0.98
  Q-wave 4 (0.7%) 2 (0.4%) 1.99 (0.36–10.87) 0.43
  Non–Q-wave 3 (0.6%) 5 (1.0%) 0.59 (0.14–2.48) 0.48
 Target-vessel reinfarction 4 (0.8%) 4 (0.8%) 0.98 (0.25–3.92) 0.98
  Q-wave 3 (0.6%) 1 (0.2%) 2.98 (0.31–28.64) 0.35
  Non–Q-wave 1 (0.2%) 3 (0.6%) 0.33 (0.03–3.15) 0.33
 Cardiac death or target-vessel reinfarction 5 (0.9%) 9 (1.7%) 0.55 (0.18–1.63) 0.28
 Any TLR 24 (4.7%) 31 (6.3) 0.74 (0.44–1.27) 0.27
 Ischemia-driven TLR 8 (1.5%) 14 (2.7) 0.55 (0.23–1.30) 0.17
 Any TVR 15 (2.9%) 21 (4.1) 0.68 (0.35–1.32) 0.25
 Ischemia-driven TVR 12 (2.3%) 16 (3.1) 0.72 (0.34–1.52) 0.39
 Major adverse cardiac events* 9 (1.7%) 19 (3.7%) 0.45 (0.20–1.00) 0.049
 Death, any reinfarction, any revascularization 35 (6.9%) 41 (8.3%) 0.82 (0.52–1.29) 0.39
 Stroke 3 (0.6%) 2 (0.4%) 1.51 (0.25–9.02) 0.65
 Definite stent thrombosis 3 (0.6%) 2 (0.4%) 1.47 (0.25–8.83) 0.67
 Definite or probable stent thrombosis 4 (0.8%) 4 (0.8%) 0.98 (0.25–3.93) 0.98
Data are number of patients (%). Hazard ratios are derived from Cox proportional hazard models. P values are 2-sided from superiority testing with a χ2 test. CI 
indicates confidence interval; TLR, target lesion revascularization; and TVR, target vessel revascularization.
*It is a composite of cardiac death, target-vessel reinfarction, and ischemia-driven target-lesion revascularization.
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among patients with STEMI undergoing primary PCI with the 
following principal findings:
1. At 2 years, BES significantly reduced the risk of the device-
oriented composite of cardiac death, target-vessel myocar-
dial infarction (TV-MI), ischemia-driven target lesion re-
vascularization (TLR), and the patient-oriented composite 
of death, any reinfarction, and any repeat revascularization.
2. The benefit of BES over BMS in terms of major cardiovas-
cular events was not only sustained but also continued to 
accrue beyond 1 year of clinical follow-up.
3. At 2 years, BES was associated with a significantly reduced 
risk of cardiac death or TV-MI and a reduced risk for the 
individual components of the primary end point including 
TV-MI and ischemia-driven TLR.
4. Very late ST occurred with similar frequency among BES- 
and BMS-treated patients beyond 1 year.
5. Compared with BMS, BES potently suppressed neointimal 
hyperplasia resulting in a lower risk of restenosis.
A key finding of this study is the continued benefit of DES 
over BMS in the prevention of MACEs during the time period 
beyond 1 year. Indeed, the clinical benefit of BES over BMS 
estimated as numbers needed to treat to prevent 1 MACE 
amounted to 24 at 1 year but further decreased to 13 at 2 
years of follow-up suggesting continued clinical benefit. Of 
note, the improved outcomes at 2 years in terms of the com-
posite primary end point of MACEs were not only driven by 
expected differences in efficacy but also extended to ischemic 
end points including a lower risk for the composite of cardiac 
death or TV-MI as well as TV-MI, a finding which has not 
been previously observed in STEMI trials comparing early-
generation DES with BMS.8,9
The continued reduction in major cardiovascular events 
between the first and second of follow-up in favor of BES 
warrants discussion because the biodegradable polymer–
based DES should theoretically have turned into a metallic 
bare stent with similar properties as BMS. The performance 
of a repeat angiography in 8% of the overall study popula-
tion did not significantly impact the outcome as evidenced in 
a sensitivity analysis. Although data from angiographic fol-
low-up studies indicate that most restenotic events leading to 
repeat revascularization occur between 6 and 12 months with 
BMS, the numerically higher event rate in terms of TLR in 
this study speaks to the fact that delayed restenosis beyond 1 
year may be more pronounced with BMS than BES. However, 
it remains speculative why the reduced risk of TLR beyond 1 
year was accompanied by numerically lower events rates for 
cardiac death and myocardial infarction because there were no 
differences in terms of definite or probable ST.
Figure 1. Time-to-event curves for the primary end point of major adverse cardiac events (composite of cardiac death, target-vessel–
related reinfarction, and ischemia-driven target-lesion revascularization) throughout 2 years (A), cardiac death (B), target-vessel–related 
reinfarction (C), and ischemia-driven target-lesion revascularization (D) for patients receiving biolimus-eluting stents with biodegradable 
polymer and patients receiving bare-metal stents. P values are 2-sided from Cox regression models χ2 test. CI indicates confidence inter-
val; and HR, hazard ratio.
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BES was also associated with a lower risk of the primary 
end point MACE (a composite of cardiac death, myocardial 
infarction, and clinically indicated TLR) compared with siroli-
mus-eluting stent–treated patients (BES 6.7% versus sirolimus-
eluting stent 15.7%; HR, 0.40; 95% CI, 0.18–0.87; P=0.02) in 
the STEMI subgroup of patients enrolled into the BES With 
Biodegradable Polymer Versus Sirolimus-Eluting Stent With 
Durable Polymer for Coronary Revascularization (LEADERS) 
trial. The favorable treatment effect of BES over sirolimus-elut-
ing stent observed in the STEMI subgroup of the LEADERS 
Figure 3. Time-to-event curves for the primary end point of major adverse cardiac events throughout 2 years with landmark analysis at 
1 year (A), cardiac death (B), target-vessel–related reinfarction (C), and ischemia-driven target-lesion revascularization (D) for patients 
receiving biolimus-eluting stents with biodegradable polymer and patients receiving bare-metal stents. P values for interaction are for dif-
ferences in hazard ratios between 0 to 1 and 1 to 2 years. HR indicates hazard ratio.
Figure 2. Time-to-event curves for definite (A) and definite or probable (B) stent thrombosis throughout 2 years. CI indicates confidence 
interval; and HR, hazard ratio.
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trial provides further support for the clinical benefit observed 
with BES in our trial. Extended follow-up beyond 1 year 
among patients with STEMI undergoing primary PCI is clini-
cally important to assess the long-term safety profile of DES 
particularly at the time after discontinuation of the routinely 
recommended 12-month duration of dual antiplatelet therapy. 
Previous studies did suggest an increased risk of very late ST 
and TV-MI beyond 1 year in patients treated with early-gener-
ation DES.8,9 We, therefore, performed detailed analyses using 
landmark techniques set at 1 year to gain insights into the risk 
profile and potential mechanisms of action of biodegradable 
polymer DES compared with BMS. Although there were no dif-
ferences in cardiac death, BES showed a significant interaction 
with time in terms of TV-MI, namely a reduced risk of TV-MI, 
compared with BMS during the first year risk reduction=80%) 
followed by a similar risk (risk reduction=2%) during the 
subsequent year of follow-up. The similar rather than increased 
risk of TV-MI associated with BES compared with BMS 
beyond 1 year is noteworthy because it differs from the previous 
experience with early-generation DES. It is explained at least 
in part by the optimized polymer-drug profile characterized by 
early drug release followed by biodegradation of the polylactid 
acid polymer resulting in a surface similar to a BMS platform 
after a period of 6 to 9 months. In addition, the antiproliferative 
drug does not only suppress neointimal proliferation thereby 
preventing TV-MI due to restenosis but may also exert an anti-
thrombotic effect in concert with the polymer,10 which is hypo-
thetically more relevant in the hypercoagulable milieu of patients 
with STEMI.11
Similar to the risk of TV-MI, we observed a trend toward a 
lower rate of ST with BES during the first year, followed by 
the absence of differences in very late definite and definite or 
Table 4. Angiographic Results
Biolimus-Eluting Stents BMS Difference (95% CI)* P Value†
No. of patients 53 50
No. of lesions 62 59
Preprocedural
 Reference vessel diameter, mm 3.05±0.51 3.00±0.44 0.05 (–0.12 to 0.22) 0.57
 Minimal lumen diameter, mm 0.52±0.57 0.48±0.59 0.04 (–0.17 to 0.25) 0.70
 Lesion length, mm 15.59±7.99 17.19±9.54 –1.60 (–4.76 to 1.57) 0.32
 Diameter stenosis, % 82.78±18.64 83.75±19.76 –0.97 (–7.88 to 5.94) 0.78
Postprocedural
 Reference vessel diameter, mm 3.08±0.57 3.06±0.48 0.02 (–0.17 to 0.21) 0.85
 Minimal lumen diameter, mm
  In-stent 2.83±0.53 2.77±0.39 0.07 (–0.10 to 0.23) 0.43
  In-segment 2.48±0.48 2.43±0.50 0.05 (–0.12 to 0.23) 0.55
 Diameter stenosis, %
  In-stent 9.04±4.61 10.30±5.03 –1.26 (–3.00 to 0.47) 0.15
  In-segment 18.39±9.11 20.48±10.80 –2.08 (–5.68 to 1.51) 0.25
13-mo follow-up‡
 No. of patients FUP 46 45
 No. of lesions FUP 54 54
 Reference vessel diameter, mm 3.07±0.61 2.92±0.52 0.15 (–0.06 to 0.37) 0.16
 Minimal lumen diameter, mm
  In-stent 2.73±0.57 1.79±0.83 0.94 (0.67 to 1.21) <0.001
  In-segment 2.37±0.47 1.75±0.80 0.62 (0.37 to 0.87) <0.001
 Diameter stenosis, %
  In-stent 12.02±7.23 39.60±25.21 –27.58 (–34.65 to –20.52) <0.001
  In-segment 21.55±8.70 41.29±24.10 –19.74 (–26.65 to –12.84) <0.001
 Binary stenosis, %
  In-stent 0 (0.00%) 14 (25.93%) –25.93 (–37.84 to –14.01) <0.001§
  In-segment 0 (0.00%) 14 (25.93%) –25.93 (–37.84 to –14.01) <0.001§
 Late loss, mm
  In-stent 0.11±0.24 0.97±0.75 –0.87 (–1.08 to –0.65) <0.001
  In-segment 0.10±0.30 0.71±0.75 –0.61 (–0.83 to –0.39) <0.001
BMS indicates bare-metal stent; CI, confidence interval; and FUP, follow-up.
*Crude difference biolimus-eluting stent (BES) vs BMS overall across all lesions (95% CI).
†Mixed model P values accounting for lesions nested within patient identifier.
‡Two patients (n=1 BES; n=1 BMS) who presented with definite stent thrombosis within 30 d were excluded from the follow-up 13-mo quantitative coronary analysis.
§All BES lesions without binary stenosis: Fisher test on culprit lesion only.
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probable ST beyond 1 year. Nevertheless, very late ST was 
not eliminated as indicated by a residual rate of 0.6% for 
BES-treated patients and 0.4% for BMS-treated patients dur-
ing the second year of follow-up. In Harmonizing Outcomes 
With Revascularization and Stents in Acute Myocardial 
Infarction (HORIZON AMI) trial,12 the rate of very late ST 
was 1.1% among paclitaxel-eluting stents and 0.6% among 
BMS-treated patients during the second year of follow-up. 
The 2-year results of the everolimus-eluting stent (EES) ver-
sus BMS in ST-segment–elevation myocardial infarction 
(EXAMINATION)13 trial comparing EES with BMS in patients 
with STEMI are consistent with this study, specifically, there 
was no difference in very late ST (EES 0.3% versus BMS 0.3%). 
Although EES in the setting of STEMI did not result in a lower 
risk of TV-MI, they were associated with a significant reduction 
in definite ST at 2 years (EES 0.8% versus BMS 2.1%; P=0.03). 
Although in the EXAMINATION trial, BMS-treated patients 
showed a significantly higher discontinuation of dual antiplate-
let therapy at 1 year (90%) compared with EES-treated patients 
(98%, P<0.001), numbers were comparable between treatment 
arms at 2 years (EES and BMS 18%) in both trials.
The similar safety profile of BES and BMS beyond 1 year 
is supported by the fact that ≈60% of patients in both treat-
ment groups discontinued routine dual antiplatelet therapy 
at 13 months and 82% at 2 years. Although observational in 
nature, the results of this study suggest that discontinuation of 
P2Y12 inhibitors at 1 year may be reasonable among patients 
with STEMI.
Compared with BMS, BES reduced the risk of TLR by 72% 
during the first year, whereas no significant reduction was 
observed during the second year. The angiographic results 
obtained at 13 months in the subgroup of 103 patients revealed 
a late lumen loss, which was similar to the one observed in 
the angiographic substudy of the biolimus-eluting stent with 
biodegradable polymer versus sirolimus-eluting stent with 
durable polymer for coronary revascularization (LEADERS)4 
trial assessed at 9 months (BES in-segment 0.08±0.45 mm; 
in-stent 0.13±0.46 mm). Although the time interval between 
9 and 13 months may be too short to ascertain relevant dif-
ferences in terms of late catch-up, the results reassuringly 
confirm the potent and sustained suppression of neointimal 
hyperplasia by the antiproliferative agent biolimus with a late 
lumen loss lower than with any early-generation DES in the 
setting of STEMI.12,14,15 The long-term efficacy outcome of 
BES is also in line with previous reports comparing BES with 
sirolimus-eluting stent in an all comers trial with a continued 
benefit of BES throughout 5 years.4 Conversely, late lumen 
loss observed with BMS used in this study was comparable 
to the one recorded in the paclitaxel-eluting stents versus 
BMSs in acute myocardial infarction (HORIZON AMI) trial12 
(in-segment/in-stent late loss BMS COMFORTABLE AMI, 
0.71±0.75 mm/0.97±0.75 mm versus BMS HORIZON AMI, 
0.59±0.64 mm/0.82±0.70 mm).
Limitation
Our results have to be interpreted in view of the following 
limitations. The trial indicated superiority on the primary 
composite outcome but was not powered to address individual 
components of efficacy or safety. Moreover, observed event 
rates were lower than anticipated. In view of the size of the 
observed treatment effect and results of previous trials, we 
consider it unlikely that estimates of efficacy would substan-
tially differ in a larger patient cohort.
The inclusion of safety outcomes in the primary composite 
outcome is meaningful because cardiac death or TV-MI may 
be device related. Event rates of cardiac death or TV-MI were 
of similar magnitude as ischemia-driven target-lesion revas-
cularization in our trial providing a similar weight of efficacy 
and safety parameters within the composite end point.
Conclusions
Our findings suggest that the use of BESs with biodegradable 
polymer in patients with STEMI is associated with continued 
clinical benefit in terms of MACEs beyond 1 year following 
routine discontinuation of dual antiplatelet therapy. Apart from 
the expected sustainability of a superior efficacy, BES was asso-
ciated with a favorable safety profile as evidenced by lower rates 
of the composite of cardiac death or TV-MI as well as TV-MI 
throughout 2 years. The latter finding is hypothesis generating 
and requires validation in appropriately designed studies.
Figure 4. Cumulative distribution curve for angio-
graphic percent diameter stenosis comparing bio-
limus-eluting stents vs bare-metal stents at 13-mo 
follow-up.
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